Salivary Duct Carcinoma, Salivary Gland Cancer
Conditions
Keywords
Positron-Emission Tomography, 68Ga-PSMA-PET/CT, 18FDG-PET/CT, Androgen deprivation therapy
Brief summary
Explorative study, which evaluates the effect of androgen deprivation therapy (ADT) on the PSMA ligand uptake on 68Ga-PSMA-PET/CT in salivary duct carcinoma patients.
Detailed description
Rationale: Prostate specific membrane antigen (PSMA) is a transmembrane protein, which is expressed on prostate cancers cells and other malignancies. Recently, several ligands have been developed that target PSMA. Linked to Gallium-68, this enables diagnostic 68Ga-PSMA-PET/CT scans. Linked to Lutetium-177 enables therapeutic 177Lu-PSMA Radioligand therapy. Most research on the diagnostic and therapeutic possibilities of PSMA has been conducted in patients with advanced prostate cancer. This research group investigates whether these findings also apply to salivary gland cancer (SGC), a rare cancer. Previously the investigators conducted a phase II 68Ga-PSMA imaging study (NCT03319641), to evaluate PSMA ligand uptake in locally advanced, recurrent and metastatic ACC and SDC (two subtypes of SGC). A relevant PSMA-ligand uptake was observed in 93% of ACC patients and 40% of SDC patients. However, since 60% of SDC patients showed low ligand uptake, these patients are not suitable for PSMA radioligand therapy. For advanced SDC, androgen deprivation therapy is often given as first-line treatment, because the majority of SDCs are androgen receptor positive. In prostate cancer, androgen deprivation therapy (ADT) can increase PSMA-ligand uptake. Therefore the aim is to investigate if ADT can increase the uptake of 68Ga-PSMA in patients with R/M SDC, as has previously been demonstrated in prostate cancer. Objective: The primary objective is to investigate if ADT can increase the uptake of 68Ga-PSMA in patients with R/M SDC. Study design: Interventional clinical trial, an explorative study. Study population: Patients with locally advanced, recurrent or metastatic (R/M) SDC AR+ and who will start ADT as standard of care.
Interventions
DIAGNOSTIC_TEST68Ga-PSMA-PET/CT
All participants in the study will be injected with 2.0 MBq/kg 68Ga-PSMA for PET/CT imaging, both pre- and post ADT.
DIAGNOSTIC_TEST18FDG-PET/CT
All participants in the study will be injected with 2.1 MBq/kg 18FDG for PET/CT imaging, both pre- and post ADT.
Sponsors
Dutch Cancer Society
Radboud University Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have the ability to provide written informed consent. * Patients must be ≥ 18 years of age. * Patients must have histological, pathological, and/or cytological confirmation of salivary duct carcinoma, androgen receptor positive. * Only patients with locally advanced, recurrent or metastatic salivary duct carcinoma can participate. * Patients must have at least one lesion with a diameter of ≥ 1.5 cm. * Patients whom intend to start androgen deprivation therapy, after this has been recommended by the treating physician as standard treatment.
Exclusion criteria
* Contra-indication for PET imaging (pregnancy, breast feeding severe claustrophobia) * Impaired renal function: MDRD \<30 ml/min/1,73 m2 * Impaired liver function: AST and ALT ALT ≥ 2.5 x ULN (≥5 x ULN for patients with liver metastases)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of patients with a change in PSMA ligand uptake after ADT | Up to 4 weeks | The percentage of patients with an androgen deprivation therapy (ADT) induced change in PSMA ligand uptake on 68Ga-PSMA-PET/CT. pre-scan: baseline (before ADT), post-scan: 3 weeks after start ADT (± 1 week). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in 18FDG uptake of tumor lesions | Up to 4 weeks | Comparison of SUV (standardized uptake value) in 18FDG-PET/CT between lesions before and 3 weeks after the initiation of ADT (± 1 week). |
| Lesions detected by 68Ga-PSMA-PET/CT pre- and post ADT | Up to 4 weeks | The number of lesions detected on 68Ga-PSMA-PET/CT imaging will be measured, both before and after ADT. |
| Change in 68Ga-PSMA uptake of tumor lesions | Up to 4 weeks | Comparison of SUV (standardized uptake value) in 68Ga-PSMA PET/CT between lesions before and 3 weeks after the initiation of ADT (± 1 week). |
| Diagnostic added value 68Ga-PSMA-PET/CT and 18FDG-PET/CT. | Up to 4 weeks | The number of lesions detected by each imaging modality (diagnostic CT, 68Ga-PSMA-PET/CT and 18FDG-PET/CT) will be measured. |
| Correlation PSMA expression and PSMA ligand uptake | Up to 6 months | The tumor uptake (SUV) will be correlated to the degree of immunohistochemical PSMA expression on the most recent tumormaterial. |
| FDG and PSMA uptake patterns of SDC disease | Up to 4 weeks | FDG and PSMA uptake patterns of SDC disease on 68Ga-PSMA-PET/CT and 18FDG-PET/CT will be measured, e.g. to explore if most lesions show both FDG and PSMA uptake, or if the lesions show a more heterogenous uptake. |
Countries
Netherlands
Outcome results
None listed